Highlight
– Vericiguat reduces the composite risk of cardiovascular death or heart failure hospitalization in patients with HFrEF across a broad risk spectrum.
– The pooled analysis from the VICTORIA and VICTOR trials includes diverse populations with and without recent worsening of heart failure.
– Both components of the composite endpoint—cardiovascular death and heart failure hospitalization—showed statistically significant reductions.
– These findings support vericiguat as an additional treatment option in contemporary guideline-directed medical therapy for HFrEF.
